Toggle Main Menu Toggle Search

ePrints

Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score

Lookup NU author(s): Dr Vinod Hegade, Dr Amardeep Khanna, Dr Lucy Walker, Dr Lin Lee Wong, Dr Jess Dyson, Professor David Jones

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

BACKGROUND:Fenofibrate (FF) has been suggested as a second-line agent in primary biliary cholangitis (PBC) patients who do not achieve adequate biochemical response to ursodeoxycholic acid (UDCA) monotherapy. Limited data exist on FF use beyond 12 months, and its long-term effects are unclear.AIM:To study the biochemical outcome of long-term (>12 months) FF treatment in combination with UDCA (FF + UDCA) in PBC patients and to determine the effect on predicted prognosis using the UK-PBC Risk Score.METHODS:This was a retrospective cohort study of all PBC patients treated in a specialist center with FF + UDCA therapy after failure to achieve biochemical response. Liver and renal biochemical indices and the UK-PBC Risk Score at baseline and at 12, 24, 36, 48, and 60 months of FF + UDCA treatment were compared. Biochemical response was assessed using the POISE trial criteria at the end of FF + UDCA treatment.RESULTS:Data from 23 patients treated with FF + UDCA combination were analyzed. The median dose of fenofibrate was 200 mg/day, and median treatment duration was 21 months (range 1-123 months). Six (26 %) patients discontinued FF within 1 year. In patients who completed 12 months (n = 17) and long-term therapy, significant decrease in ALP was seen at 12 (p = 0.0002), 24 (p = 0.002), and 36 (p = 0.03) months. More than 75 % patients met the POISE criteria of ALP response at all study time points. There was no significant improvement in the 5-, 10-, and 15-year UK-PBC Risk Scores after FF + UDCA treatment. No significant renal impairment or adverse events were reported.CONCLUSION:The long-term treatment of PBC patients with fenofibrate as an adjunct to UDCA is safe and effective in improving ALP, but the treatment did not significantly reduce the estimated probability of liver-related death or need for liver transplantation.


Publication metadata

Author(s): Hegade VS, Khanna A, Walker LJ, Wong LL, Dyson JK, Jones DEJ

Publication type: Article

Publication status: Published

Journal: Digestive Diseases and Sciences

Year: 2016

Volume: 61

Issue: 10

Pages: 2037-3044

Online publication date: 19/07/2016

Acceptance date: 19/07/2016

ISSN (print): 0163-2116

ISSN (electronic): 1573-2568

Publisher: Springer

URL: http://dx.doi.org/10.1007/s10620-016-4250-y

DOI: 10.1007/s10620-016-4250-y


Altmetrics

Altmetrics provided by Altmetric


Actions

    Link to this publication


Share